Not All Birth Control Carries the Same Brain Tumor Risk, Study Finds.

A large new study has found that some hormonal contraceptives are linked to a higher risk of meningioma — the most common type of brain tumor in adults, and one that is usually benign. But the headline needs context: the increase applies to specific products, the absolute risk remains very small, and experts say the findings shouldn’t push most people away from birth control.

The research, published in JAMA Network Open, drew on 25 years of Danish national health records covering roughly three million women. It is the first study of its kind to show that only certain contraceptives carry this association — not hormonal birth control as a whole.

What a Meningioma Actually Is

Meningiomas grow in the membranes surrounding the brain and spinal cord. They account for roughly 38% to 42% of all primary central nervous system tumors, making them the most common brain tumor in adults — and they are typically noncancerous and treatable.

One detail has long caught researchers’ attention: meningiomas occur far more often in women than in men. That imbalance points toward hormones. More than 60% of these tumors carry progesterone receptors, which offers a plausible biological reason why progestogen — a synthetic form of progesterone — might influence their growth.

Not All Birth Control Behaves the Same

The central message of the study is that the risk is not spread evenly across methods. The Danish data pointed to a modestly increased meningioma risk with several hormonal products, with the clearest signal from:

• Injectable medroxyprogesterone (known by the brand name Depo-Provera) — the strongest association, roughly a fourfold relative increase
• High-dose hormonal IUDs containing 52 mg of levonorgestrel, particularly with use beyond a year
• Combined estrogen–progestogen pills and desogestrel-only pills — more modest signals

Notably, lower-dose hormonal IUDs showed no excess risk.

Why the injection stands out likely comes down to dose and delivery. It releases a high dose of synthetic progestogen into the bloodstream, sustaining elevated hormone levels throughout the body for months. Localized methods, such as low-dose IUDs that release hormone mainly within the uterus, don’t produce that same system-wide exposure.

Putting the Risk in Perspective

Context matters in the other direction, too. Contraception delivers real, well-documented benefits: it prevents unintended pregnancy, lowers the risk of ovarian and endometrial cancer, and helps manage heavy or painful periods. Any decision has to weigh those benefits against a small, uncertain risk — not treat the risk in isolation.

Where the Evidence Disagrees

The picture isn’t fully settled. An earlier French national study published in The BMJ reported a substantially higher risk with medroxyprogesterone used for more than a year, but found no increased meningioma risk with levonorgestrel — the hormone in IUDs and emergency contraceptives like Plan B. The Danish analysis, by contrast, did flag high-dose levonorgestrel IUDs.

That disagreement is a reason for caution in both directions: these are observational studies, which cannot establish cause and effect, and researchers say more work is needed to clarify how duration of use affects risk for each progestogen.

Symptoms Worth Knowing

Meningiomas often grow slowly and may cause no symptoms at all. When they do, warning signs can include:

• persistent headaches
• memory problems
• changes in vision or hearing

These symptoms have many causes far more common than a brain tumor. Still, if they are persistent or unexplained — especially after long-term use of a high-dose progestogen — they are worth raising with a doctor.

What This Means for Your Choices

Nobody should stop contraception abruptly based on a news headline. The practical response is a conversation, not a panic.

Clinicians suggest a few reasonable principles: use the lowest effective dose of progestogen-containing methods for the shortest appropriate duration; consider personal and family history of meningioma when choosing; and know that non-hormonal options exist, including copper IUDs and barrier methods. In the United States, the FDA updated the labeling for the medroxyprogesterone injection in December 2025 to note a possible link with meningiomas.

Ultimately, the right method depends on individual priorities, medical history, and what each person needs from contraception — a decision best made with a healthcare provider who knows that history.